CHPG Sodium saltCAS# 1303993-73-8 |
- Celastrol
Catalog No.:BCN5986
CAS No.:34157-83-0
- BMS-345541
Catalog No.:BCC1423
CAS No.:547757-23-3
- Bay 65-1942 free base
Catalog No.:BCC1408
CAS No.:600734-02-9
- Bay 65-1942 HCl salt
Catalog No.:BCC1409
CAS No.:600734-06-3
- Bay 65-1942 R form
Catalog No.:BCC1410
CAS No.:758683-21-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1303993-73-8 | SDF | Download SDF |
PubChem ID | 124081038 | Appearance | Powder |
Formula | C8H7ClNNaO3 | M.Wt | 223.59 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 50 mM in water and to 50 mM in DMSO | ||
Chemical Name | sodium;(2R)-2-amino-2-(2-chloro-5-hydroxyphenyl)acetate | ||
SMILES | C1=CC(=C(C=C1O)C(C(=O)[O-])N)Cl.[Na+] | ||
Standard InChIKey | KZRZZIISUUINJT-OGFXRTJISA-M | ||
Standard InChI | InChI=1S/C8H8ClNO3.Na/c9-6-2-1-4(11)3-5(6)7(10)8(12)13;/h1-3,7,11H,10H2,(H,12,13);/q;+1/p-1/t7-;/m1./s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Sodium salt of the selective mGlu5 agonist CHPG. |
CHPG Sodium salt Dilution Calculator
CHPG Sodium salt Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 4.4725 mL | 22.3624 mL | 44.7247 mL | 89.4494 mL | 111.8118 mL |
5 mM | 0.8945 mL | 4.4725 mL | 8.9449 mL | 17.8899 mL | 22.3624 mL |
10 mM | 0.4472 mL | 2.2362 mL | 4.4725 mL | 8.9449 mL | 11.1812 mL |
50 mM | 0.0894 mL | 0.4472 mL | 0.8945 mL | 1.789 mL | 2.2362 mL |
100 mM | 0.0447 mL | 0.2236 mL | 0.4472 mL | 0.8945 mL | 1.1181 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- DL-AP5 Sodium salt
Catalog No.:BCC7753
CAS No.:1303993-72-7
- 2-Oxokolavenol
Catalog No.:BCN4716
CAS No.:130395-82-3
- Pungiolide A
Catalog No.:BCN8128
CAS No.:130395-54-9
- Decinnamoyltaxagifine
Catalog No.:BCN7329
CAS No.:130394-69-3
- Batimastat (BB-94)
Catalog No.:BCC1223
CAS No.:130370-60-4
- AC 45594
Catalog No.:BCC7544
CAS No.:13037-86-0
- MI-773 (SAR405838)
Catalog No.:BCC5648
CAS No.:1303607-60-4
- MI-773
Catalog No.:BCC5155
CAS No.:1303607-07-9
- Cathayanon I
Catalog No.:BCN3678
CAS No.:1303438-52-9
- Cathayanon H
Catalog No.:BCN3570
CAS No.:1303438-51-8
- CI 988
Catalog No.:BCC7430
CAS No.:130332-27-3
- H-D-Phe-OMe.HCl
Catalog No.:BCC3013
CAS No.:13033-84-6
- (RS)-MCPG disodium salt
Catalog No.:BCC7756
CAS No.:1303994-09-3
- Paulownin
Catalog No.:BCN6160
CAS No.:13040-46-5
- (-)-Catechin gallate(CG)
Catalog No.:BCN5330
CAS No.:130405-40-2
- A-71623
Catalog No.:BCC7354
CAS No.:130408-77-4
- Peucedanocoumarin I
Catalog No.:BCN3434
CAS No.:130464-55-0
- Peucedanocoumarin II
Catalog No.:BCN3435
CAS No.:130464-56-1
- Peucedanocoumarin III
Catalog No.:BCN3471
CAS No.:130464-57-2
- Batimastat sodium salt
Catalog No.:BCC2075
CAS No.:130464-84-5
- A 68930 hydrochloride
Catalog No.:BCC7104
CAS No.:130465-39-3
- ent-11alpha-Hydroxyabieta-8(14),13(15)-dien-16,12alpha-olide
Catalog No.:BCN7330
CAS No.:130466-20-5
- L-655,708
Catalog No.:BCC7023
CAS No.:130477-52-0
- TC-F 2
Catalog No.:BCC6147
CAS No.:1304778-15-1
Selective mGluR5 receptor antagonist or agonist provides neuroprotection in a rat model of focal cerebral ischemia.[Pubmed:11743947]
Brain Res. 2001 Dec 20;922(2):173-9.
Activation of group I metabotropic glutamate receptors (mGluR) has been implicated in the pathophysiology of acute central nervous system injury. However, the relative roles of the two group I subtypes, mGluR1 or mGluR5, in such injury has not been well examined. We compared the effects of treatment with the newly developed, selective mGluR5 antagonist 2-methyl-6-phenylethynylpyridine (MPEP) and the selective mGluR5 agonist (R,S)-2-chloro-5-hydroxyphenylglycine (CHPG) in a rat intraluminal filament model of temporary middle cerebral artery occlusion (MCAo). Rats were administered MPEP or CHPG i.c.v. beginning 15 or 135 min after induction of ischemia for 2 h. Infarct size was measured after either 22 or 70 h of reperfusion, and neurological function was quantified at 2, 24, 48 and 72 h. Treatment with MPEP or CHPG at 15 min reduced 24 h infarct volume by 61 and 44%, respectively. The neuroprotective effects were dose dependent. Delaying MPEP treatment until 135 min eliminated the neuroprotective effects. In other studies, using early MPEP treatment (15 min) at optimal doses, infarct volume was reduced by 44% at 72 h and this was correlated with significant neurological recovery. These data suggest that both MPEP and CHPG are neuroprotective when administered after focal cerebral ischemia. In separate, recent studies we found that although MPEP does act as an mGluR5 antagonist and blocks agonist induced phosphoinositide hydrolysis, it also serves as a non-competitive NMDA antagonist; in contrast, other results indicate that CHPG mediated neuroprotection may reflect anti-apoptotic activity. Therefore, both types of compounds may prove to have therapeutic potential for the treatment of stroke.
Antagonism of the mGlu5 agonist 2-chloro-5-hydroxyphenylglycine by the novel selective mGlu5 antagonist 6-methyl-2-(phenylethynyl)-pyridine (MPEP) in the thalamus.[Pubmed:10455248]
Br J Pharmacol. 1999 Jul;127(5):1057-9.
Our previous work has shown that Group I mGlu receptors participate in thalamic sensory processing in vivo. However, unequivocal demonstration of mGlu5 participation has not been possible due to the lack of specific ligands. We have therefore made a preliminary study of the in vivo actions of the agonist (R,S)-2-Chloro-5-hydroxyphenylglycine [CHPG] and the novel mGlu5 antagonist 6-methyl-2-(phenylethynyl)-pyridine [MPEP] in order to characterize their suitability for functional studies. Iontophoretically administered MPEP selectively antagonized excitatory responses of single rat thalamic neurones to CHPG compared to the broad-spectrum mGlu agonist (1S,3R)-1-aminocyclopentane-1,3-dicarboxylate. In contrast, the established mGlu1 and mGlu5 antagonist (S)-4-carboxyphenylglycine reduced responses to both agonists. These findings are the first demonstration of an in vivo action of CHPG and its antagonism by a selective mGlu5 antagonist. Furthermore MPEP appears to be a good tool for functional studies of mGlu5.
(RS)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but no mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus.[Pubmed:9144665]
Neuropharmacology. 1997 Feb;36(2):265-7.
A new phenylglycine derivative, (RS)-2-chloro-5-hydroxyphenylglycine (CHPG), has been synthesized and shown to selectively activate mGlu5a receptors, compared to mGlu1 alpha receptors, when expressed in CHO cells. This selective mGlu5 receptor agonist also potentiates NMDA-induced depolarizations in rat hippocampal slices. CHPG may be a useful tool for studying the role of mGlu5 receptors in the central nervous system.